CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth

[Tokyo, Japan; April 24, 2024] – CellTech Accelerator, the first cell and gene therapy accelerator in Asia, is pleased to announce the signing of a Memorandum of Understanding (MOU) with Cyto-Facto Inc., a prominent Japanese CDMO company specialized in manufacturing cell and gene therapy (CGT) products. The MOU sets the stage for collaborative efforts aimed at advancing the development and business growth of CGT in multiple Asia Pacific regions.

Fostering Collaboration as Regenerative Medicine Industry Matures

Under the terms of the MOU, both parties will explore various avenues of cooperation with the goal of enhancing the landscape of the biotech industry. Following productive discussions, the companies deepened their understanding of the latest advancements in GCT, focusing on how these advancements will drive expansion in related businesses within the GCT field and augment the industrialization of new start-ups.

The MOU outlines key areas of collaboration, including business development, CDMO consultation meetings, long-term service agreements, and co-branding initiatives. This involves joint efforts to facilitate the CGTs in target regions through activities such as CDMO partnership, customized services, and consultations. Additionally, CDMO consultation meetings will be conducted to address potential issues encountered by biotech companies, serving as a platform for identifying and discussing challenges. The parties will explore the possibility of entering into long-term service agreements to address specific or complex process development issues faced by biotech companies, and both parties will collaborate on co-branding efforts across various platforms to amplify their presence and showcase their joint endeavors in the CGT industry.

Building An Ecosystem that Drives Innovation in the CGT Sector 

Celltech Innovation Accelerator, focuses on advancing CGT. It supports entrepreneurs in translating cell therapy technologies into practical applications by providing financial support, consulting, and commercialization training services. The company aims to establish an entrepreneurial ecosystem and collaborate with investors and industry partners to drive technology commercialization. Additionally, it offers a comprehensive ecosystem that supports all aspects of a cell and gene therapy venture’s growth. 

Cyto-Facto Inc., based in Japan, provides contract manufacturing services for gene and cell preparations compliant with J-GMP and PIC/S GMP standards. Their offerings include process development, technology transfer, and GMP documentation maintenance. Additionally, they offer consultation on manufacturing, commercialization, and quality control testing of CGT products, along with integration development of manufacturing management systems to ensure efficiency and compliance.

Author

GeneOnline